STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
29 APRIL 2022 at 10.50 EEST
Composition of the Nomination Committee of Orion Corporation
The Board of Directors of Orion Corporation has appointed the following persons to the Nomination Committee of the company:
- Annika Ekman
- Petteri Karttunen
- Timo Maasilta
- Hilpi Rautelin
- Mikael Silvennoinen
- Heikki Westerlund
Heikki Westerlund was appointed as Chairman of the Committee.
The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.
The essentials of the working order of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/Orion-group/corporate-governance/board-of-directors/board-committees/, a page in the Corporate Governance section of the Orion Group internet website.
President and CEO
SVP, Corporate Functions
Timo Lappalainen, President and CEO
tel. +358 10 426 3692
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are currently neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.